Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $6.5 million.

  • Aytu Biopharma's Other Operating Expenses rose 534.47% to $6.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $32.4 million, marking a year-over-year increase of 2749.72%. This contributed to the annual value of $32.9 million for FY2025, which is 2750.14% up from last year.
  • Latest data reveals that Aytu Biopharma reported Other Operating Expenses of $6.5 million as of Q4 2025, which was up 534.47% from $5.8 million recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Other Operating Expenses peaked at $14.4 million during Q4 2022, and registered a low of -$53.1 million during Q1 2022.
  • Its 5-year average for Other Operating Expenses is -$2.0 million, with a median of $6.2 million in 2024.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first crashed by 42274.81% in 2021, then surged by 22498.27% in 2022.
  • Aytu Biopharma's Other Operating Expenses (Quarter) stood at -$11.5 million in 2021, then soared by 224.98% to $14.4 million in 2022, then tumbled by 57.49% to $6.1 million in 2023, then grew by 0.93% to $6.2 million in 2024, then rose by 5.34% to $6.5 million in 2025.
  • Its Other Operating Expenses was $6.5 million in Q4 2025, compared to $5.8 million in Q3 2025 and $14.0 million in Q2 2025.